**Figure 4.** **Construction of m6A-related risk signature.** (**A**) Identification of m6A-related prognostic DEGs. (**B**) The survival difference between the high- (*n* = 39) and low-risk groups (*n* = 38). (**C**) Time-dependent ROC curves of m6A risk signature. (**D**) PCA plot of m6A risk signature. (**E**) t-SNE plot of m6A risk signature. (**F**) ROC curves of m6A risk signature and ACC clinical parameters. (**G**) Risk plots of m6A risk signature. (**H**) The summary of HNRNPC and RBM15 mutations. (**I**) The summary of mutation types. (**J**) The mutation types of HNRNPC. (**K**) The mutation types of RBM15. (**L**) The heatmap of m6A risk signature. The relationships between m6A-related risk levels and the clinicopathological characteristics of ACC were determined by Kolmogorov–Smirnov test. Overexpression is presented in red and low expression is green. DEGs, differentially expressed genes; ROC, receiver operating characteristic curve; PCA, principal component analysis; s-SNE, t-distributed stochastic neighbor embedding; ^{*}*P* < 0.05, ^{**}*P* < 0.01.